Added final trance using dividends today |
Not GSK-specific, whole market a sea of red today. |
This is being relentlessly dumped. |
Dive dive dive! 1300 incoming. |
Most UK shares are not responding to anything |
And regular good product/business news, yet share price not responding. |
Zantac issue almost cleared up and for a lot less than feared yet share price not responding. |
Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA editing in humans. The update on the GSK-partnered prospect sent Wave’s share price up 63%.
GSK paid $170 million to close a deal that included global rights to WVE-006 in 2022. Wave will wrap up the current study of WVE-006 and then hand over to GSK, which is on the hook for up to $525 million in milestones, for further development. |
I've bought back in here after quite a while. Looking for diversity and yield - as well as great things. (Time is a great healer .....) Apologies to all longs in advance - my timing is usually poor. |
Any morning gains seem to be routinely reversed with Wall Street opening |
VERY IMPORTANT:
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents
Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials - 26 March 2025 assigned as action date for FDA decision.
Gepotidacin could be the first in a new class of oral antibiotic treatment for uUTIs in over 20 years. |
We need them to disagree a lot.. |
The US disagree |
Currency movements have also been a headwind. |
Yes, there's been a lot of good news flow all year and the neutral response in the share price seemed to have been attributed to the litigation issue. Now that's gone, there's still some ill sentiment. It will take time, rather than positive news for that to dissolve. |
I must say I feel a lot less bullish after witnessing the very poor share price reaction to the Zantac news. Seems like we need a lot of good news flow before this can get motoring again. |
Many brokers citing 1820 to 1850p (Citigroup 1900p) |
Guggenheim cuts target price to 1785p from 1898p |
Your >25 years dividends (especially if used to buy more GSK as you go) would have been worth a great deal more than the 3% that you are up. Do the calculation and consider continuing with GSK for your income portfolio. |
 Brexit wasn't great for pharma's. We lost the EMEA hq, its harder to attract EU scientists, the contract labs that need to work on a fast turnaround have lost business due to customs delays. We have no say in making regulations but still have meet them (de-regulation in medicine won't happen, we always have to meet EP/USP/JP standards). Perhaps there are some gains, but as someone who visits pharmas regularly I've never been told one.
Pharma regulation needs to cover major populations. Whilst there has been a lot of harmonisation in the cGMP requirements, it would be impractical to introduce our own. It would send the cost sky rocketing. And if we failed to meet others, it simply wouldn't be allowed to be sold. Regulation (particularly data integrity) is here to stay.
---
I'm tempted to add more here. I've held GSK as long as I can remember - at least 25 years and I'm up 3%. That excludes dividends. But as I move towards an income portfolio and the clinical news has generally been positive it should hopefully be dull and worthy for the next 25 |
More positive Phase III news:,
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps
· Primary endpoints met with statistically significant reduction in nasal polyp size and nasal obstruction versus placebo plus standard of care, at 52 weeks
· Depemokimab is an ultra-long-acting biologic administered once every six months
· Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) experience a range of symptoms which are widely underestimated and often sub-optimally treated |
That is the thing. We all need to respect that other people can have alternative views. There are obviously benefits and negatives to EU membership and also Brexit. It is a complicated world. |
.. much more than we gained from exiting.I respect your opinion though, even if I don't agree with it. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
